The Technical Analyst
BioCorRx Inc. [BICX]
Exchange: PNK Industry: Medical Care Facilities
BioCorRx Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.750
America/New_York / 3 mai 2024 @ 13:22
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6.61 mill |
| EPS: | -0.450 |
| P/E: | -1.670 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 8.82 mill |
| Avg Daily Volume: | 0.0010 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.670 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.20x |
| Company: PE -1.670 | industry: PE 8.44 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.735 (-198.06%) $-1.485 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.715 - 0.785 ( +/- 4.67%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-30 | Lucido Louis C. | Buy | 21 552 | Common Stock, par value $0.001 |
| 2024-03-28 | Galligan Joseph J | Buy | 5 566 | Common Stock, par value $0.001 |
| 2024-01-02 | Galligan Joseph J | Buy | 6 173 | Common Stock, par value $0.001 |
| 2024-03-28 | Granier Brady James | Buy | 16 698 | Stock Option |
| 2024-03-28 | Murthy Harsha | Buy | 5 566 | Common Stock, par value $0.001 |
| INSIDER POWER |
|---|
| 100.00 |
| Last 98 transactions |
| Buy: 908 641 | Sell: 0 |
Forecast:
15:02 - $0.760
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.750 (0.00% ) |
| Volume | 0.0004 mill |
| Avg. Vol. | 0.0010 mill |
| % of Avg. Vol | 38.65 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BICX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BICX
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
Latest Press Releases
2024-04-03 08:30:00 - Press Release
Biocorrx Pharmaceuticals Inc. Awarded New Patent For Novel Compound To Treat Pain, Depression, And Schizophrenia
Anaheim, ca, april 03, 2024 (globe newswire) -- via newmediawire -- biocorrx inc. (otcqb: bicx) (the “company”), a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary biocorrx pharmaceuticals inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the united states patent and trademark office (uspto).
2024-04-02 08:30:00 - Press Release
Biocorrx Reports Business Update For 2023
Anaheim, ca, april 02, 2024 (globe newswire) -- via newmediawire — biocorrx inc. (otcqb: bicx) (the “company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended december 31, 2023, and reported on recent corporate developments.
2024-02-28 10:49:00 - Press Release
Biocorrx Pharmaceuticals Inc. Awarded Nida Grant Of Approximately $11 Million Over Three Years For Research On Bicx104, A Naltrexone Implant In Combination With Bupropion For The Treatment Of Mud
Anaheim, ca, feb. 28, 2024 (globe newswire) -- via newmediawire – biocorrx inc. (otcqb: bicx) (the “company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced that its subsidiary biocorrx pharmaceuticals inc. has been awarded a 3-year grant for approximately $11 million from the national institute on drug abuse (nida), part of the national institutes of health (nih), under award number u01da059994 for the development of bicx104, a subcutaneous, long-duration naltrexone implantable pellet, alone or in conjunction with bupropion for the treatment of methamphetamine use disorder (mud).
2024-02-08 09:52:00 - Press Release
Biocorrx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate Devarney To The Board Of Directors
Anaheim, ca, feb. 08, 2024 (globe newswire) -- via newmediawire – biocorrx inc. (otcqb: bicx) (the “company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary biocorrx pharmaceuticals inc., has appointed kate beebe devarney, ph.d. to its board of directors.
2024-01-09 08:30:00 - Press Release
Biocorrx Appoints Renowned Investment And Capital Markets Executive Louis Lucido As President
Anaheim, ca, jan. 09, 2024 (globe newswire) -- via newmediawire – biocorrx inc. (otcqb: bicx) (the “company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced the appointment of louis lucido as interim president of the company, effective immediately through january 31, 2024, and he will assume the formal role as president on february 1, 2024. mr. lucido will remain a member of the board of directors. additionally, the company announced that brady granier has submitted his letter of resignation as president of biocorrx inc. and chief executive officer of biocorrx pharmaceuticals, a subsidiary of the company, effective january 31, 2024...
Latest News
2023-01-27 08:30:00 - GlobeNewsWire
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
2022-10-24 11:30:00 - Newsfile Corp
BioCorRx to Present at the LD Micro Main Event XV on October 25th
Anaheim, California--(Newsfile Corp. - October 24, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc.
2022-09-06 08:30:00 - GlobeNewsWire
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
ANAHEIM, CA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO, and Director of BioCorRx, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.
2022-05-31 09:00:00 - GlobeNewsWire
BioCorRx to Present at the LD Micro Invitational XII on June 7th
ANAHEIM, CA, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the LD Micro Invitational XII which is being held on June 7– 9, 2022, at the Four Seasons Westlake Village, California.
2022-03-22 08:30:00 - GlobeNewsWire
BioCorRx to Participate in Two Upcoming Conferences
ANAHEIM, CA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will be participating in two upcoming conferences.
2022-03-02 08:30:00 - Newsfile Corp
BioCorRx to Present at the Q1 Investor Summit Conference on March 9th
Anaheim, California--(Newsfile Corp. - March 2, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will present at the Q1 Investor Summit, hosted by the Investor Summit Group, being held virtually on March 8-9, 2022.Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director and CEO of BioCorRx Pharmaceuticals, are...
2021-11-10 14:47:00 - Newsfile Corp
BioCorRx to Present at the Q4 Investor Summit Conference on November 16th
Anaheim, California--(Newsfile Corp. - November 10, 2021) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021.Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director and CEO of BioCorRx Pharmaceuticals, are...
2021-10-07 08:30:00 - GlobeNewsWire
BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant
ANAHEIM, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent application with the Russian Patent Office (Rospatent) for a biodegradable implant including naltrexone. Several of the claims in the application are intended to cover BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), being developed under BioCorRx Pharmaceuticals, Inc., the Company's controlled R&D subsidiary.
2021-09-29 12:16:00 - GlobeNewsWire
BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th
ANAHEIM, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it will be presenting at LD Micro's 14th annual Main Event on Tuesday, October 12, 2021, at 1:30 PM PT/4:30 PM ET at the Luxe Sunset Bel-Air in Los Angeles. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., and Brady Granier, President and Director, CEO of BioCorRx Pharmaceuticals, will present at the conference.
2021-09-22 08:30:00 - GlobeNewsWire
BioCorRx Files Patent Application with USPTO for Naltrexone Implant
ANAHEIM, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent application with the U.S. Patent and Trademark Office (USPTO) for a biodegradable implant including naltrexone. Several of the claims in the application are intended to cover BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), being developed under BioCorRx Pharmaceuticals, Inc., the Company's controlled R&D subsidiary.